Expression Profile of Micro RNAs (miRNAs) in Bladder Cancer Patients in a Tertiary Referral Hospital
DOI:
https://doi.org/10.54212/27068048.v9i2.7Keywords:
Micro RNA in bladder cancer, biomarkers in bladder cancer, MiRNAs, miR-96, miR-183, miR-92a, miR-100 and miR-143, miR15b5p, miR5905pAbstract
Aims: To describe the expression profile of Micro RNAs (miRNAs) in patients with bladder cancer patients. The greatest advance in the search for a biomarker has been seen since 2007, the year in which it was identified that Micro RNAs are altered in cancer, understanding that miRNAs can function as tumor suppressors or as oncogenes, in more recent studies it is identified that miRNAs are highly stable and resistant to handling and can be determined by various methods in fresh or fixed tissue, in serum, plasma, urine and saliva, making them candidates for biomarkers for early detection, monitoring and treatment efficacy in bladder cancer. Material and methods: Observational, prospective, cross-sectional and descriptive study in patients diagnosed with bladder cancer between October 1, 2018 and December 1, 2019 with a non-randomized, non-probabilistic sampling by criteria, comparing the expression profile of MiRNAs in serum, against a healthy population, excluding patients with some other type of synchronous cancer. Results: The expression profile of MiRNAs in serum was obtained from 33 patients diagnosed with bladder cancer and 33 cancer-free patients with similar demographic characteristics, finding similar behavior to that of the current literature in our population. Conclusions : Under-expression and overexpression of MiRNAs were identified with similar results to the international literature, so it is considered that MiRNAs have a high potential to be used as biomarkers for bladder cancer.
Downloads
References
Goldman A. Manual de enfermería oncológica. Instituto Nacional del Cáncer Argentina 2014.
Organization WH. Global Health Observatory. Geneva: World Health Organization; 2018. 2018.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018;68:394-424. https://doi.org/10.3322/caac.21492 DOI: https://doi.org/10.3322/caac.21492
Organization WH. Cancer control: knowledge into action. WHO guide for effective programmes: prevention: World Health Organization; 2007.
Helenius M, Brekkan E, Dahlman P, Lönnemark M, Magnusson A. Bladder cancer detection in patients with gross haematuria: computed tomography urography with enhancement-triggered scan versus flexible cystoscopy. Scandinavian journal of urology 2015;49:377-81. https://doi.org/10.3109/21681805.2015.1026937 DOI: https://doi.org/10.3109/21681805.2015.1026937
Sánchez-Carbayo M, Urrutia M, Hernández-Cerceño ML, de Buitrago JMG, Navajo JA. Citoqueratinas (UBC y CYFRA 21-1) y proteínas de la matriz nuclear (NMP22) como marcadores tumorales en la orina en el diagnóstico del cáncer vesical. Medicina Clínica 2000;114:361-6. https://doi.org/10.1016/S0025-7753(00)71298-X DOI: https://doi.org/10.1016/S0025-7753(00)71298-X
Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urologia internationalis 2015;94:1-24. https://doi.org/10.1159/000369357 DOI: https://doi.org/10.1159/000369357
Rodriguez RHM, Rueda OB, Ibarz L. Tumor vesical: presente y futuro. Medicina Clínica 2017;149:449-55. https://doi.org/10.1016/j.medcli.2017.06.009 DOI: https://doi.org/10.1016/j.medcli.2017.06.009
Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Science translational medicine 2012;4:127rv3-rv3. https://doi.org/10.1126/scitranslmed.3003180 DOI: https://doi.org/10.1126/scitranslmed.3003180
Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52. https://doi.org/10.1038/nature06913 DOI: https://doi.org/10.1038/nature06913
Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. International journal of physiology, pathophysiology and pharmacology 2011;3:140.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nature reviews Clinical oncology 2011;8:467. https://doi.org/10.1038/nrclinonc.2011.76 DOI: https://doi.org/10.1038/nrclinonc.2011.76
Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature reviews cancer 2006;6:259. https://doi.org/10.1038/nrc1840 DOI: https://doi.org/10.1038/nrc1840
Rico-Rosillo MG, Vega-Robledo GB, Oliva-Rico D. Importancia de los microARN en el diagnóstico y desarrollo de enfermedades. Revista Médica del Instituto Mexicano del Seguro Social 2014;52:302-7.
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research 2008;18:997. https://doi.org/10.1038/cr.2008.282 DOI: https://doi.org/10.1038/cr.2008.282
Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ. miR‐21‐5p, miR‐141‐3p, and miR‐205‐5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. The Prostate 2019;79:88-95. https://doi.org/10.1002/pros.23714 DOI: https://doi.org/10.1002/pros.23714
Musquera M, Mengual L, Ribal MJ. Diagnóstico no invasivo en cáncer de vejiga: Nuevos marcadores moleculares y futuras perspectivas. Archivos Españoles de Urología 2013;1:487-94.
Yamada Y, Enokida H, Kojima S, et al. MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer science 2011;102:522-9. https://doi.org/10.1111/j.1349-7006.2010.01816.x DOI: https://doi.org/10.1111/j.1349-7006.2010.01816.x
Motawi TK, Rizk SM, Ibrahim TM, Ibrahim IAR. Circulating microRNAs, miR‐92a, miR‐100 and miR‐143, as non‐invasive biomarkers for bladder cancer diagnosis. Cell biochemistry and function 2016;34:142-8. https://doi.org/10.1002/cbf.3171 DOI: https://doi.org/10.1002/cbf.3171
Tölle A, Blobel CC, Jung K. Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017. Biomarkers in medicine 2018;12:667-76. https://doi.org/10.2217/bmm-2017-0392 DOI: https://doi.org/10.2217/bmm-2017-0392
Tölle A, Buckendahl L, Jung K. Plasma miR 15b 5p and miR 590 5p for distinguishing patients with bladder cancer from healthy individuals. Oncology reports 2019;42:1609-20. https://doi.org/10.3892/or.2019.7247 DOI: https://doi.org/10.3892/or.2019.7247
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Cecil Paul Tarot Chocooj, José Gadú Campos Salcedo y Cristóbal Díaz Gómez
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
